Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transcriptome analysis of interferon receptor locus dosage correction in a mouse model of Down syndrome

ABSTRACT: Transcriptome analysis of interferon receptor locus dosage correction in a mouse model of Down syndrome

PROVIDER: PRJNA906623 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR22428400_1.fastq.gz	Fastqsanger.gz
	SRR22428400_2.fastq.gz	Fastqsanger.gz
	SRR22428401_1.fastq.gz	Fastqsanger.gz
	SRR22428401_2.fastq.gz	Fastqsanger.gz
	SRR22428402_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 192

Similar Datasets

Transcriptome analysis of interferon receptor locus dosage correction in a mouse model of Down syndrome

Project description:This SuperSeries is composed of the SubSeries listed below.

2023-03-21 | GSE219039 | GEO

Transcription dosage compensation does not occur in Down syndrome

Project description:Transcription dosage compensation does not occur in Down syndrome

| PRJNA962941 | ENA

Mediator kinase inhibition suppresses hyperactive interferon signaling in Down syndrome

Project description:Individuals with Down syndrome have a increased likelihood of suffering from inflammatory and autoimmune conditions, due to the presence of four interferon receptors on chromosome 21. Transcription of genes plays a key role in the interferon response, and the Mediator kinases, CDK8 and CDK19, are essential in potentiating this transcription. Given the role CDK8/19 play in the interferon response, and the fact that selective inhibitors of these kinases exist (such as Cortistatin A), it is possible that targetting Mediator kinase activity may alleviate symptoms of chronic inflammation in Down syndrome.

2023-09-12 | GSE220652 | GEO

Mediator kinase inhibition suppresses hyperactive interferon signaling in Down syndrome II

2024-09-01 | GSE249549 | GEO

Mediator kinase inhibition suppresses hyperactive interferon signaling in Down syndrome

Project description:Mediator kinase inhibition suppresses hyperactive interferon signaling in Down syndrome

| PRJNA910594 | ENA

Down Syndrome

Project description:Down Syndrome

| PRJNA804910 | ENA

Mediator kinase inhibition suppresses hyperactive interferon signaling in Down syndrome II

Project description:Mediator kinase inhibition suppresses hyperactive interferon signaling in Down syndrome II

| PRJNA1049466 | ENA

Dissection of a Down syndrome-associated trisomy to separate the gene dosage-dependent and -independent effects of an extra chromosome

Project description:Trisomy is a form of aneuploidy associated with embryonic and postnatal abnormalities in mammals. Understanding the underlying mechanisms involved in mutant phenotypes is broadly important and may lead to new strategies to treat clinical manifestations in individuals with trisomies, such as trisomy 21 (Down syndrome). While increased gene dosage effects due to a trisomy may account for the mutant phenotypes, there is also the possibility that phenotypic consequences of a trisomy can arise because of the presence of a freely segregating extra chromosome with its own centromere, i.e., a ‘free trisomy’ independent of gene dosage effects. Presently, there are no reports of attempts to functionally separate these two types of effects. To fill this gap, here we describe a strategy that employed two new mouse models of Down syndrome, Ts65Dn;Df(17)2Yey/+ and Dp(16)1Yey/Df(16)8Yey. Both models carry triplications of the same 103 human chromosome 21 gene orthologs; however, only Ts65Dn;Df(17)2Yey/+ mice carry a free trisomy. Comparative analysis of these two models revealed the gene dosage-independent effect of an extra chromosome at the phenotypic level for the first time, as reflected by impairments of Ts65Dn;Df(17)2Yey/+ males in T-maze tests when compared with Dp(16)1Yey/Df(16)8Yey males. Results from the transcriptomic analysis suggest the extra chromosome may play a major role in trisomy-associated expression alterations of disomic genes beyond gene dosage effects. This model system can now be used to deepen our mechanistic understanding of this common human aneuploidy and obtain new insights into the effects of free trisomies in other human diseases such as cancers.

2023-04-19 | GSE229563 | GEO

Down syndrome CNVs - samples

Project description:Down syndrome CNV genotyping data

| EGAD00010000466 | EGA

Down syndrome SNPs - samples

Project description:Down syndrome SNP genotyping data

| EGAD00010000464 | EGA